EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding radiation to osimertinib keep lung cancer in check?
Disease control OngoingThis phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new drug called APG-1252 combined with the standard pill osimertinib in 80 people with EGFR-positive non-small cell lung cancer that has stopped responding to other targeted therapies. The goal is to find a safe dose and see if the combination can s…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC